Literature DB >> 21656347

Home-based exercise therapy in patients with ankylosing spondylitis: effects on pain, mobility, disease activity, quality of life, and respiratory functions.

Ebru Aytekin1, Nil Sayıner Caglar, Levent Ozgonenel, Sule Tutun, Dilay Yilmaz Demiryontar, Saliha Eroglu Demir.   

Abstract

The home-based exercise therapy recommended to the patients with ankylosing spondylitis (AS) is a simply applicable and cheap method. The aim of this study was to investigate the effects of home-based exercise therapy on pain, mobility, function, disease activity, quality of life, and respiratory functions in patients with AS. Eighty patients diagnosed with AS according to the modified New York criteria were included in the study. Home-based exercise program including range of motion, stretching, strengthening, posture, and respiratory exercises was practically demonstrated by a physiotherapist. A training and exercise manual booklet was given to all patients. Patients following home-based exercise program five times a week at least 30 min per session (exercise group) for 3 months were compared with those exercising less than five times a week (control group). Visual analog scale pain (VASp) values at baseline were significantly higher in the exercise group. The exercise group showed improvements in VASp, tragus-wall distance, morning stiffness, finger-floor distance, modified Schober's test, chest expansion, the Bath Ankylosing Spondylitis Disease Activity Index, the Bath Ankylosing Spondylitis Functional Index, Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL), forced expiratory volume in first second, and forced vital capacity at third month. There was significant difference in ASQoL scores between the two groups in favor of the exercise group at third month. Regular home-based exercise therapy should be a part of main therapy in patients with AS. Physicians should recommend that patients with AS do exercise at least five times a week at least 30 min per session.

Entities:  

Mesh:

Year:  2011        PMID: 21656347     DOI: 10.1007/s10067-011-1791-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  34 in total

Review 1.  Treatment of spondyloarthropathies. Recent advances and prospects in 2001.

Authors:  M Dougados
Journal:  Joint Bone Spine       Date:  2001-12       Impact factor: 4.929

2.  Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis.

Authors:  L C Doward; A Spoorenberg; S A Cook; D Whalley; P S Helliwell; L J Kay; S P McKenna; A Tennant; D van der Heijde; M A Chamberlain
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

3.  Lung findings on high-resolution computed tomography in idiopathic ankylosing spondylitis--correlation with clinical findings, pulmonary function testing and plain radiography.

Authors:  I P Casserly; H M Fenlon; E Breatnach; S M Sant
Journal:  Br J Rheumatol       Date:  1997-06

4.  Relationship between psychological status and disease activity and quality of life in ankylosing spondylitis.

Authors:  Ozlem Baysal; Bekir Durmuş; Yüksel Ersoy; Zuhal Altay; Kazım Senel; Kemal Nas; Mahir Uğur; Arzu Kaya; Ali Gür; Akın Erdal; Ozge Ardıçoğlu; Ibrahim Tekeoğlu; Remzi Cevik; Kadir Yıldırım; Ayhan Kamanlı; Ayşegül Jale Saraç; Saliha Karatay; Salih Ozgocmen
Journal:  Rheumatol Int       Date:  2010-03-10       Impact factor: 2.631

5.  Exercise and changes in health status in patients with ankylosing spondylitis.

Authors:  Z Uhrin; S Kuzis; M M Ward
Journal:  Arch Intern Med       Date:  2000-10-23

6.  Comparison of group-based exercise versus home-based exercise in patients with ankylosing spondylitis: effects on Bath Ankylosing Spondylitis Indices, quality of life and depression.

Authors:  Hale Karapolat; Yeşim Akkoc; Ismail Sari; Sibel Eyigor; Servet Akar; Yeşim Kirazli; Nurullah Akkoc
Journal:  Clin Rheumatol       Date:  2007-11-06       Impact factor: 2.980

7.  The Turkish versions of the Bath Ankylosing Spondylitis and Dougados Functional Indices: reliability and validity.

Authors:  Altinay Goksel Karatepe; Yesim Akkoc; Servet Akar; Yesim Kirazli; Nurullah Akkoc
Journal:  Rheumatol Int       Date:  2004-07-10       Impact factor: 2.631

8.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

Review 9.  Physiotherapy interventions for ankylosing spondylitis.

Authors:  H Dagfinrud; T K Kvien; K B Hagen
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

10.  Are swimming or aerobic exercise better than conventional exercise in ankylosing spondylitis patients? A randomized controlled study.

Authors:  H Karapolat; S Eyigor; M Zoghi; Y Akkoc; Y Kirazli; G Keser
Journal:  Eur J Phys Rehabil Med       Date:  2009-07-23       Impact factor: 2.874

View more
  20 in total

1.  [Sports and exercise therapy in inflammatory rheumatic diseases].

Authors:  Wolfgang Hartung; Philipp Sewerin; Benedikt Ostendorf
Journal:  Z Rheumatol       Date:  2021-03-08       Impact factor: 1.372

2.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.3 Nonpharmaceutical therapeutic measures].

Authors:  U Kiltz; W Mau; U Smolenski; U Repschläger; E Böhle; M Stemmer; U Oberschelp; E Schneider; B Swoboda; H Böhm; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

Review 3.  Effects of physical therapy for the management of patients with ankylosing spondylitis in the biological era.

Authors:  Erika Giannotti; Sabina Trainito; Giovanni Arioli; Vincenzo Rucco; Stefano Masiero
Journal:  Clin Rheumatol       Date:  2014-05-07       Impact factor: 2.980

4.  Home-based exercise therapy in ankylosing spondylitis: short-term prospective study in patients receiving tumor necrosis factor alpha inhibitors.

Authors:  Semra Yigit; Zerrin Sahin; Saliha Eroglu Demir; Deniz Hatun Aytac
Journal:  Rheumatol Int       Date:  2012-01-05       Impact factor: 2.631

5.  A qualitative study of the impact of Crohn's disease from a patient's perspective.

Authors:  Jeanette Wilburn; James Twiss; Karen Kemp; Stephen P McKenna
Journal:  Frontline Gastroenterol       Date:  2016-05-12

6.  Core set of recommendations for patients with ankylosing spondylitis concerning behaviour and environmental adaptations.

Authors:  Ernst Feldtkeller; Gudrun Lind-Albrecht; Martin Rudwaleit
Journal:  Rheumatol Int       Date:  2013-03-29       Impact factor: 2.631

7.  Tomography-guided palisade sacroiliac joint radiofrequency neurotomy versus celecoxib for ankylosing spondylitis: a open-label, randomized, and controlled trial.

Authors:  Yongjun Zheng; Minghong Gu; Dongping Shi; Mingli Li; Le Ye; Xiangrui Wang
Journal:  Rheumatol Int       Date:  2014-02-12       Impact factor: 2.631

8.  LLLT for the management of patients with ankylosing spondylitis.

Authors:  D Stasinopoulos; K Papadopoulos; D Lamnisos; A Stergioulas
Journal:  Lasers Med Sci       Date:  2016-01-21       Impact factor: 3.161

9.  [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

Authors:  U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

Review 10.  [Core set of behavioral recommendations for patients with ankylosing spondylitis].

Authors:  E Feldtkeller; G Lind-Albrecht; M Rudwaleit
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.